Evidence map›Paper›PMID 32835128›Full record

ArticleContemporary clinical trials communications2020

Managing oncology clinical trials during COVID-19 pandemic.

Roberto J Arai, Camila M V Moniz, André T C Chen, Milena P Mak, Roger Chammas, Paulo M Hoff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Roberto J AraiInstituto do Câncer do Estado de São Paulo - ICESP, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.
Camila M V MonizInstituto do Câncer do Estado de São Paulo - ICESP, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.
André T C ChenInstituto do Câncer do Estado de São Paulo - ICESP, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.
Milena P MakInstituto do Câncer do Estado de São Paulo - ICESP, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.
Roger ChammasInstituto do Câncer do Estado de São Paulo - ICESP, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.
Paulo M HoffInstituto do Câncer do Estado de São Paulo - ICESP, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

São Paulo city is the epicenter of the Brazilian COVID-19 pandemic. The Instituto do Cancer do Estado de São Paulo is currently conducting 161 multinational sponsored trials plus 116 in house studies in the oncologic population. There are 242 currently active participants and 180 patients in follow-up. The management of the tightly controlled environment of clinical research becomes a challenge, and the Food and Drug Administration set of priority recommendations for patient safety while maintaining study integrity. Fast adaptations are necessary, and actions coalesce to participant protection from COVID-19. We pointed out critical processes for adjustments, and we believe that our experience may help other academic health centers.

Indexed as

COVID-19Oncology clinical trials

Identifiers

PMID32835128
PMCPMC7424329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.